Firmagon
Prostatic Neoplasms
Treatment
2 FDA approvals
0 Active Studies for Firmagon
Treatment for
Prostatic Neoplasms
What is Firmagon
Degarelix
The Generic name of this drug
Treatment Summary
Degarelix is a medication used to treat advanced prostate cancer. It works by blocking the release of hormones in the pituitary gland that trigger testosterone production, thus reducing the amount of testosterone in the body. Chemically, it is a synthetic decapeptide amide containing seven unnatural amino acids. The FDA approved Degarelix in December 2008.
Firmagon
is the brand name
Firmagon Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Firmagon
Degarelix
2009
4
Approved as Treatment by the FDA
Degarelix, otherwise called Firmagon, is approved by the FDA for 2 uses including Advanced Prostate Cancer and Prostatic Neoplasms .
Advanced Prostate Cancer
Prostatic Neoplasms
Effectiveness
How Firmagon Affects Patients
Degarelix is a drug that blocks the release of hormones from the pituitary gland, such as luteinizing hormone(LH) and follicle-stimulating hormone (FSH). This, in turn, reduces the amount of testosterone released by the testes. The drug works by blocking the GnRH receptor, which prevents the binding of a natural hormone called GnRH.
How Firmagon works in the body
Degarelix works by blocking receptors in the pituitary gland from releasing hormones that stimulate prostate cancer growth. By blocking these hormones, it helps to slow the growth and reduce the size of prostate cancer.
When to interrupt dosage
The quantity of Firmagon is contingent upon the recognized condition. The dosage shifts, as per the method of delivery (e.g. Powder, metered - Subcutaneous or Injection, powder, for solution - Subcutaneous) featured in the table beneath.
Condition
Dosage
Administration
Prostatic Neoplasms
120.0 mg, , 80.0 mg, 20.0 mg/mL, 40.0 mg/mL
Powder, for solution - Subcutaneous, Subcutaneous, , Powder, for solution, Injection, powder, for solution, Injection, powder, for solution - Subcutaneous, Powder, metered, Powder, metered - Subcutaneous
Warnings
Firmagon Contraindications
Condition
Risk Level
Notes
risk of embryo/fetal lethality and abortion
Do Not Combine
There are 20 known major drug interactions with Firmagon.
Common Firmagon Drug Interactions
Drug Name
Risk Level
Description
Hydroxyzine
Major
The risk or severity of QTc prolongation can be increased when Degarelix is combined with Hydroxyzine.
Mobocertinib
Major
The risk or severity of QTc prolongation can be increased when Degarelix is combined with Mobocertinib.
Ziprasidone
Major
The risk or severity of QTc prolongation can be increased when Degarelix is combined with Ziprasidone.
Abexinostat
Minor
The risk or severity of QTc prolongation can be increased when Degarelix is combined with Abexinostat.
Aceprometazine
Minor
The risk or severity of QTc prolongation can be increased when Degarelix is combined with Aceprometazine.
Firmagon Toxicity & Overdose Risk
Common side effects of degarelix therapy include injection site reactions such as pain, redness, swelling, or hardness, hot flashes, weight gain, and elevated liver enzymes.
Firmagon Novel Uses: Which Conditions Have a Clinical Trial Featuring Firmagon?
Currently, 3 active studies are being conducted to analyze the potential of Firmagon in treating Advanced Prostate Cancer.
Condition
Clinical Trials
Trial Phases
Prostatic Neoplasms
0 Actively Recruiting
Firmagon Reviews: What are patients saying about Firmagon?
5
Patient Review
9/20/2019
Firmagon for Advanced Form of Prostate Cancer
5
Patient Review
3/31/2016
Firmagon for Advanced Form of Prostate Cancer
5
Patient Review
10/11/2011
Firmagon for Advanced Form of Prostate Cancer
4.7
Patient Review
9/15/2011
Firmagon for Advanced Form of Prostate Cancer
4.3
Patient Review
11/12/2015
Firmagon for Advanced Form of Prostate Cancer
3.7
Patient Review
9/12/2013
Firmagon for Advanced Form of Prostate Cancer
Patient Q&A Section about firmagon
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
How long can you stay on Firmagon?
"A recent study published in The Journal of Urology found that degarelix (Firmagon) is effective and well tolerated in patients with advanced prostate cancer beyond 3 years."
Answered by AI
Does Firmagon cure prostate cancer?
"The drug degarelix is not a cure for prostate cancer, however it is effective in treating the cancer by reducing the amount of testosterone in the body, which is needed for the cancer to grow and spread."
Answered by AI
What is Firmagon for prostate cancer?
"The hormone that the cancer cells need is testosterone.
Degarelix is a hormone therapy drug, also known by its brand name Firmagon, which treats advanced hormone dependent prostate cancer. Prostate cancer is considered hormone dependent when the cancer cells need a hormone, such as testosterone, to promote growth."
Answered by AI
Is Firmagon considered chemotherapy?
"Firmagon (degarelix) works by halting the production of a hormone that stimulates growth in some prostate cancers.
Firmagon (degarelix) is not classified as a chemotherapy medication because it does not work by killing fast-growing cells in the body. Instead, Firmagon (degarelix) halts the production of a hormone that stimulates growth in some prostate cancers."
Answered by AI